Pulmonx Corp SEC Filings

FMR LLC and Abigail P. Johnson report beneficial ownership of 2,179,993.02 shares of Pulmonx Corp common stock, representing 5.4% of the outstanding class. FMR LLC is shown with sole voting power over 2,175,878 shares and sole dispositive power over 2,179,993.02 shares; Abigail P. Johnson is reported with sole dispositive power over 2,179,993.02 shares and no voting power. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

The filing refers to an accompanying Exhibit 99 and incorporates prior powers of attorney by reference. No other person is identified as holding more than 5% of the common stock.

Steven S. Williamson, President & CEO and a director of Pulmonx Corporation (LUNG), reported transactions on Form 4 showing routine insider activity. On 09/02/2025 he disposed of 5,118 shares and 4,530 shares of the issuer's common stock at a price of $1.60 per share. The filings state both sales were made to cover tax withholding obligations related to vested restricted stock units granted on March 15, 2024 and March 3, 2025.

The report also discloses that the reporting person acquired 2,500 shares under the Issuer's 2020 Employee Stock Purchase Plan on 08/15/2025. Following the reported transactions the filing lists beneficial ownership amounts of 363,497 and 358,967 shares in the non-derivative table lines, reflecting the post-transaction holdings disclosed by the reporting person.

Mehul Joshi, Chief Financial Officer and Principal Accounting Officer of Pulmonx Corporation (LUNG), reported two share dispositions on 09/02/2025 tied to tax withholding for vested restricted stock units (RSUs). The Form 4 shows sales of 4,271 shares at $1.60 per share to cover tax withholding for RSUs granted May 6, 2024, and sales of 3,665 shares at $1.60 per share to cover tax withholding for RSUs granted March 3, 2025.

Following these transactions the filing reports beneficial ownership amounts of 212,154 shares and 208,489 shares respectively; the filing also discloses the reporting person purchased 2,500 shares under the issuers 2020 Employee Stock Purchase Plan on August 15, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Joshi.

Pulmonx Corporation (LUNG) reporting person Geoffrey Beran, Chief Commercial Officer, disclosed multiple share dispositions on 09/02/2025. The Form 4 shows four separate sales of common stock at $1.60 per share to satisfy tax withholding tied to vested restricted stock units granted on March 1, 2022; March 1, 2023; March 1, 2024; and March 3, 2025. The reported quantities sold were 707, 1,799, 1,575, and 2,462 shares respectively, leaving beneficial ownership reported after each sale of 385,624, 383,825, 382,250, and 379,788 shares. The filing is signed by an attorney-in-fact on 09/03/2025.

David Aaron Lehman, identified as General Counsel and officer of Pulmonx Corporation (ticker LUNG), reported four separate non-derivative stock dispositions on 09/02/2025. The Form 4 shows Mr. Lehman sold 929, 3,541, 2,068 and 3,231 shares, each at $1.60 per share. Each sale is explained as occurring to cover tax withholding obligations tied to Restricted Stock Units that vested from grants dated March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025, respectively. The filing reports the reporting-person’s beneficial ownership following these transactions as 272,110, 268,569, 266,501 and 263,270 shares (direct ownership) after each reported disposition. The Form 4 is signed by Mr. Lehman on 09/03/2025.